MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp.’s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.
At the 53rd Annual Meeting and ToxExpo of the Society of Toxicology in Phoenix, n3D delivered a poster session presentation titled, “A Novel High-Concept Assay for Drug Toxicity Screening.” The largest event of its kind, the Society’s annual meeting brought together more than 6,000 toxicologists from more than 50 countries.
Earlier this month, n3D shared a booth at the 105th Annual Meeting of the American Association for Cancer Research in San Diego. A premiere cancer research event, the meeting was host to about 18,000 researchers, patient advocates and other professionals in the cancer field from around the world.
By presenting and exhibiting at such landmark events, n3D is helping to spread the word amongst international researchers about its incredible breakthrough technology, the BiO Assay. The BiO Assay is the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech currently on the market.
“These events are how the latest knowledge in the fields of toxicology and cancer research is spread,” said RBCC CEO Kimberly Palmer. “They are important showcases for new technologies such as the BiO Assay, and they’re only the beginning of the international brand awareness campaign that our joint venture has planned for 2014.”
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.